Recently, the Fidelio and Figaro-DKD randomized clinical trials (RCT) showed that finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduced the risk of CKD progression and cardiovascular events compared to placebo in patients with diabetes and CKD (Bakris et al., 2020; Pitt et al., 2021). Here, NR3C2 is linked to chronic kidney disease.